Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | BCL2 | P10415 | 3/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19820871 | 0.89 | STAT3 (0.57) | STAT3ALDH1A1BCL2MCL1MAPT | |
| SCHEMBL12960696 | 0.85 | ALDH1A1 (0.56) | STAT3ALDH1A1MAPTKMT2AHTT | |
| SCHEMBL19824423 | 0.80 | STAT3 (0.49) | STAT3ALDH1A1MAPTKMT2AHTT | |
| SCHEMBL17690053 | 0.78 | STAT3 (0.56) | STAT3ALDH1A1BCL2MCL1MAPT | |
| SCHEMBL16917433 | 0.76 | STAT3 (0.76) | STAT3ALDH1A1BCL2MCL1MAPT | |
| Napabucasin SCHEMBL29349770 | 0.72 | STAT3 (1.00) | STAT3ALDH1A1BCL2MCL1MAPT | |
| SCHEMBL12640087 | 0.72 | STAT3 (0.75) | STAT3ALDH1A1BCL2MCL1MAPT | |
| Napabucasin SCHEMBL1883845 | 0.72 | STAT3 (1.00) | STAT3ALDH1A1BCL2MCL1MAPT | |
| SCHEMBL38650880 | 0.72 | STAT3 (0.69) | STAT3ALDH1A1BCL2MCL1MAPT | |
| SCHEMBL12640086 | 0.71 | STAT3 (0.73) | STAT3ALDH1A1BCL2MCL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3050566-B1 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2018-11-28 | — | — | EP | claimed |
| US-20210024482-A1 | Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway Inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-20200039948-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3050566-B1 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180030022-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030022-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9745278-B2 | Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745278-B2 | Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20120252763-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252763-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2009036099-A1 | A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252763-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | STAT3, JAK2, STAT5B | STAT3 1/4885ALDH1A1 810/4885BCL2 529/4885 |
| US-20180030022-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | STAT3, JAK2, STAT5B | STAT3 1/4885ALDH1A1 765/4885BCL2 470/4885 |
| US-20210024482-A1 | Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway Inhibitors | STAT3, STAT5B, JAK2 | STAT3 1/4885ALDH1A1 588/4885BCL2 315/4885 |
| US-20200039948-A1 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS | STAT3, JAK2, STAT5B | STAT3 1/4885ALDH1A1 765/4885BCL2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.